研究单位：[1]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Hangzhou,Zhejiang,China[2]Liaoning Tumor Hospital & Institute[3]Shanxi Province Cancer Hospital[4]Sichuan Cancer Hospital and Research Institute[5]The Second Affiliated Hospital of Harbin Medical University
研究目的：
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR).
